May 9th 2024
The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free survival in newly diagnosed, high-risk endometrial cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Physicians Discuss Immunotherapy Discontinuation in Endometrial Cancer
September 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed trials of immune checkpoint inhibition and when to discontinue treatment in patients with endometrial cancer. This is the second of 2 articles based on this event.
Read More
Selecting Therapy for dMMR/MSI-H Endometrial Cancer After Chemotherapy
August 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jubilee Brown, MD, discussed the treatment options for a patient with endometrial cancer who relapsed following resection and again following a complete response to chemotherapy. This is the first of 2 articles based on this event.
Read More
FDA Approves Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
July 31st 2023FDA approval has been granted to dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient and microsatellite instability-high primary advanced or recurrent endometrial cancer.
Read More
Dostarlimab Plus Chemotherapy Shows Similar HRQOL Results in Patients With Endometrial Cancer
June 4th 2023New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.
Read More
Novel Treatment Strategies in Endometrial Cancer
Closing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.
Watch
Novel Triplet Therapy in Patients With Metastatic Uterine Serous Carcinoma
Collaborative discussion on the advent of triplet therapy in patients with metastatic uterine serous carcinoma and clinical data behind this strategy.
Watch
Patient Case 3: Metastatic Uterine Serous Carcinoma
Expert Robert L. Coleman, MD, details the final patient case and provides an overview of metastatic uterine serous carcinoma.
Watch
dMMR Recurrent EC: Practical Advice on Adverse Event Management
Key opinion leaders in the field of endometrial carcinoma provide advice on adverse event management, focusing on immune checkpoint inhibitor therapy.
Watch
Dostarlimab in dMMR Recurrent EC: Data From GARNET
Robert L. Coleman, MD, and Krishnansu S. Tewari, MD, reflect on data from the GARNET clinical trial of dostarlimab in dMMR recurrent endometrial carcinoma.
Watch
Pembrolizumab in dMMR Recurrent EC: Data From KEYNOTE-158
Shared insight on the utilization of pembrolizumab in dMMR recurrent endometrial carcinoma in the context of the KEYNOTE-158 clinical trial.
Watch